Astex welcomes positive, new data showing breast cancer drug, Kisqali® (ribociclib), cuts risk of death by up to a third when given with hormone therapy
• Cedazuridine and decitabine, administered orally as a fixed-dose combination (ASTX727), met the primary endpoint of decitabine exposure equivalence of total 5-day dosing between oral ASTX727 and IV decitabine in the phase 3 ASCERTAIN study in MDS and CMML patients
• The study confirmed that the safety profile and clinical activity of the cedazuridine and decitabine fixed-dose combination was similar to that observed in the phase 1/2 study and similar to the expected clinical profile of decitabine IV
Instinctif Partners’ Corporate and Capital Markets practice has made two Managing Partner promotions in its UK business.
Nick Woods, who leads the Financial Services team, has become the company’s youngest ever Managing Partner, while Melanie Toyne-Sewell has been promoted within the firm’s Life Sciences team.
Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications has closed a further round of investment. The £550k funding round was led by Cambridge Enterprise and five angel investors – all of whom followed initial seed investments made in April 2018. Joining the original investors is biotech entrepreneur and founder member of the Cambridge Angels, Dr Andy Richards CBE.
Agility Health Tech is delighted to announce they are now managing the communications on behalf of Stevenage Bioscience Catalyst, marking an exciting development in the business relationship between the two organisations.
About Agility Health Tech
With over 25 years’ experience, Agility Health Tech is a full service consulting and communications agency specialising in the healthcare and life science sectors. From product development to business strategy and marcomms, Agility Health Tech can help advance your products and raise your profile.
AMSBIO reports on a recent published paper** by the Howard Hughes Medical Institute at the Massachusetts Institute of Technology (MIT) investigating why epithelial cells grown in monolayers on a plastic dish are worse at segregating their chromosomes than epithelial cells in vivo or in 3D organoid cultures.
We are happy to announce the below adversting offer from New Scientist for our members.
Standard Branded Advert - £299 (reduced from £599)
• Advert branded with logo live for up to 28 days